Accelerated Longitudinal Gait Speed Decline in HIV-Infected Older Men
- PMID: 26102450
- PMCID: PMC4624470
- DOI: 10.1097/QAI.0000000000000731
Accelerated Longitudinal Gait Speed Decline in HIV-Infected Older Men
Abstract
Background: Gait speed predicts functional decline, disability, and death and is considered a biomarker of biological aging. Changes in gait speed in persons aging with HIV may provide an important method of gauging health and longevity in an under assessed population. The objective of this study was to evaluate and quantify the rate of gait speed decline in HIV-infected (HIV⁺) men compared with HIV-uninfected (HIV⁻) men.
Methods: The study was nested in the Multicenter AIDS Cohort Study. The primary outcome was usual gait speed in meters per second measured between 2007 and 2013. Differences in the rate of gait speed decline and the incidence of clinically slow gait (<1.0 m/s) were assessed using multivariate linear regression models and Cox proportional hazards models, respectively.
Results: A total of 2025 men (973 HIV⁺ and 1052 HIV⁻) aged 40 years and older contributed 21,187 person-visits (9955 HIV⁺ and 11,232 HIV⁻) to the analysis. Average gait speeds at the age 50 years were 1.24 and 1.19 m/s in HIV⁻ and HIV⁺ men, respectively (P < 0.001). In fully adjusted models, gait speed decline averaged 0.009 m/s per year after age 50 years (P < 0.001); this decline was 0.025 m/s per year greater in HIV⁺ men (P < 0.001). Moreover, HIV⁺ men had a 57% greater risk of developing clinically slow gait (adjusted hazard ratio = 1.57, 95% confidence interval: 1.27 to 1.91).
Conclusions: These findings indicate a faster rate of functional decline in HIV-infected men, suggesting greater risks of disability and death with advancing age.
Figures
References
-
- CDC Estimated HIV incidence in the United States, 2007-2010. HIV Surveillance Supplemental Report. 2012;17(4)
-
- Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunology and allergy clinics of North America. 2003;23(1):15–39. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 AI035042/AI/NIAID NIH HHS/United States
- R01AI093520/AI/NIAID NIH HHS/United States
- R03 AG040594/AG/NIA NIH HHS/United States
- P30 AI094189/AI/NIAID NIH HHS/United States
- K23 AG050260/AG/NIA NIH HHS/United States
- R03AG040594/AG/NIA NIH HHS/United States
- K24 AI120834/AI/NIAID NIH HHS/United States
- U01-AI35042/AI/NIAID NIH HHS/United States
- U01 AI035041/AI/NIAID NIH HHS/United States
- UM1 AI035043/AI/NIAID NIH HHS/United States
- K01 AI093197/AI/NIAID NIH HHS/United States
- U01-AI35041/AI/NIAID NIH HHS/United States
- U01-AI35039/AI/NIAID NIH HHS/United States
- U01 AI035040/AI/NIAID NIH HHS/United States
- U01 AI035039/AI/NIAID NIH HHS/United States
- K01AI093197/AI/NIAID NIH HHS/United States
- U01-AI35040/AI/NIAID NIH HHS/United States
- K01AG048765/AG/NIA NIH HHS/United States
- UL1 TR000424/TR/NCATS NIH HHS/United States
- R01 AI093520/AI/NIAID NIH HHS/United States
- 1P30AI094189/AI/NIAID NIH HHS/United States
- K23AG050260/AG/NIA NIH HHS/United States
- UL1-TR000424/TR/NCATS NIH HHS/United States
- UM1-AI35043/AI/NIAID NIH HHS/United States
- K01 AG048765/AG/NIA NIH HHS/United States
